Cargando…
The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor bl...
Autores principales: | García-Carro, Clara, Vergara, Ander, Agraz, Irene, Jacobs-Cachá, Conxita, Espinel, Eugenia, Seron, Daniel, Soler, María José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617211/ https://www.ncbi.nlm.nih.gov/pubmed/31212945 http://dx.doi.org/10.3390/jcm8060864 |
Ejemplares similares
-
Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020) -
Revisiting Experimental Models of Diabetic Nephropathy
por: Giralt-López, Anna, et al.
Publicado: (2020) -
Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model
por: Vergara, Ander, et al.
Publicado: (2021) -
Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019) -
A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2021)